You are here: Industry Insights > Upjohn

News List

Mylan-UpJohn merger as Viatris provides opportunity to focus on biosimilar launch and uptake expresspharma
March 17, 2021
Following the news that the European Medicines Agency (EMA) has approved Kixelle, Biocon/Mylan’s biosimilar of Novo Nordisk’s Novolog/NovoRapid (insulin aspart).
Mylan, Pfizer Receive EC Approval for Proposed Combination of Mylan and Upjohn americanpharmaceuticalreview
September 22, 2020
Mylan and Pfizer announced the companies have received final approval from the European Commission (EC) for the proposed combination of Mylan and Pfizer's Upjohn business.
Mylan Shareholders Approve Proposed Combination with Upjohn americanpharmaceuticalreview
July 10, 2020
Mylan announced its shareholders overwhelmingly voted to approve the proposed transaction combining Mylan and Upjohn, a division of Pfizer, at the company's general meeting of shareholders.
Mylan and Pfizer delay Upjohn merger amid coronavirus pandemic pharmaceutical-technology
March 30, 2020
Mylan’s merger with Pfizer’s off-patent branded drugs unit Upjohn is now expected to close in the second half of this year due to the coronavirus pandemic.
Mylan and Upjohn Join Forces contractpharma
August 05, 2019
Creates new global pharma company; revenues expected in the $20bn range.
Mylan and Upjohn, a division of Pfizer, to combine worldpharmanews
July 30, 2019
HERTFORDSHIRE, England & PITTSBURGH & Mylan N.V. (Nasdaq: MYL) and Pfizer Inc. (NYSE: PFE) today announced a definitive agreement to combine Mylan with Upjohn, Pfizer's off-patent branded and generic established medicines business ...
Mylan, Upjohn Announce New Combined Business americanpharmaceuticalreview
July 30, 2019
Mylan and Pfizer announced a definitive agreement to combine Mylan with Upjohn, Pfizer's off-patent branded and generic established medicines business, creating a new global pharmaceutical company.